Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Latest Action
Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 is a legislative measure introduced in the 119th Congress aimed at continuing or renewing existing provisions designed to expedite the development and availability of therapies for Amyotrophic Lateral Sclerosis (ALS). The bill has been passed by the House and received in the Senate, where it has been read twice and placed on the Senate Legislative Calendar. Specific details about the bill's provisions, including mechanisms, funding, or programmatic elements, are not provided in the available source data.
This bill seeks to reauthorize efforts to speed up access to treatments for ALS, currently under consideration in the Senate with limited publicly available detail on its specific content or scope.
- The bill is focused on accelerating access to critical therapies for ALS patients.
- It is a reauthorization act, indicating continuation or renewal of prior legislative efforts.
- The bill has passed the House and is pending further action in the Senate as of July 2026.
['Individuals diagnosed with ALS', 'Medical researchers and developers working on ALS therapies', 'Healthcare providers involved in ALS treatment', 'Federal agencies responsible for drug approval and health research, potentially including the FDA and NIH']
['Lack of publicly available full bill text limits assessment of funding sources and program implementation details.', 'Potential challenges in oversight and enforcement cannot be evaluated without detailed provisions.', 'Unclear policy tradeoffs or impacts on other health priorities due to absence of detailed legislative language.']
The bill is part of ongoing legislative efforts to address ALS treatment development and access, reflecting a continuation of prior congressional actions. It has moved from the House to the Senate and is awaiting further consideration, consistent with the legislative process for health-related reauthorization bills.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential acceleration of ALS therapy development could influence research priorities and funding allocation within federal health agencies.', 'Reauthorization may impact regulatory processes related to drug approval timelines for ALS treatments.', 'Enhanced access to therapies might affect healthcare delivery systems and patient care protocols.']
The absence of the full bill text and a detailed summary restricts transparency and comprehensive analysis. Stakeholders and the public lack access to critical information needed to evaluate the bill's provisions, funding, and oversight mechanisms. Monitoring future disclosures and legislative updates will be essential for informed oversight.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.